179 related articles for article (PubMed ID: 11468510)
1. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.
Carr A; Mazorra Z; Alonso DF; Mesa C; Valiente O; Gomez DE; Perez R; Fernandez LE
Melanoma Res; 2001 Jun; 11(3):219-27. PubMed ID: 11468510
[TBL] [Abstract][Full Text] [Related]
2. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma.
Alonso DF; Gabri MR; Guthmann MD; Fainboim L; Gomez DE
Int J Oncol; 1999 Jul; 15(1):59-66. PubMed ID: 10375594
[TBL] [Abstract][Full Text] [Related]
3. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
Gabri MR; Ripoll GV; Alonso DF; Gómez DE
J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
Ravindranath MH; Brazeau SM; Morton DL
Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
[TBL] [Abstract][Full Text] [Related]
5. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.
Mazorra Z; Mesa C; Fernández A; Fernández LE
Cancer Immunol Immunother; 2008 Dec; 57(12):1771-80. PubMed ID: 18351335
[TBL] [Abstract][Full Text] [Related]
7. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity.
Guthmann MD; Bitton RJ; Carnero AJ; Gabri MR; Cinat G; Koliren L; Lewi D; Fernandez LE; Alonso DF; Gómez DE; Fainboim L
J Immunother; 2004; 27(6):442-51. PubMed ID: 15534488
[TBL] [Abstract][Full Text] [Related]
8. Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.
Ravindranath MH; Kelley MC; Jones RC; Amiri AA; Bauer PM; Morton DL
Int J Cancer; 1998 Jan; 75(1):117-24. PubMed ID: 9426699
[TBL] [Abstract][Full Text] [Related]
9. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors.
Carr A; Mullet A; Mazorra Z; Vázquez AM; Alfonso M; Mesa C; Rengifo E; Pérez R; Fernández LE
Hybridoma; 2000 Jun; 19(3):241-7. PubMed ID: 10952412
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.
Carr A; Rodríguez E; Arango Mdel C; Camacho R; Osorio M; Gabri M; Carrillo G; Valdés Z; Bebelagua Y; Pérez R; Fernández LE
J Clin Oncol; 2003 Mar; 21(6):1015-21. PubMed ID: 12637465
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).
Estevez F; Carr A; Solorzano L; Valiente O; Mesa C; Barroso O; Sierra GV; Fernandez LE
Vaccine; 1999 Aug; 18(1-2):190-7. PubMed ID: 10501249
[TBL] [Abstract][Full Text] [Related]
12. An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.
Dohi T; Nores G; Hakomori S
Cancer Res; 1988 Oct; 48(20):5680-5. PubMed ID: 3167827
[TBL] [Abstract][Full Text] [Related]
13. Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.
Venier C; Guthmann MD; Fernández LE; Fainboim L
Clin Exp Immunol; 2007 Feb; 147(2):379-88. PubMed ID: 17223981
[TBL] [Abstract][Full Text] [Related]
14. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.
Labrada M; Clavell M; Bebelagua Y; León Jd; Alonso DF; Gabri MR; Veloso RC; Vérez V; Fernández LE
Expert Opin Biol Ther; 2010 Feb; 10(2):153-62. PubMed ID: 20088712
[TBL] [Abstract][Full Text] [Related]
15. Ganglioside profiles of experimental melanomas and of their melanosomal fractions.
Vedralová E; Borovanský J; Hach P
Melanoma Res; 1995 Apr; 5(2):87-92. PubMed ID: 7620344
[TBL] [Abstract][Full Text] [Related]
16. Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides.
Segatori VI; Otero LL; Fernandez LE; Gomez DE; Alonso DF; Gabri MR
In Vivo; 2012; 26(4):609-17. PubMed ID: 22773575
[TBL] [Abstract][Full Text] [Related]
17. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
18. A novel ganglioside, de-N-acetyl-GM3 (II3NeuNH2LacCer), acting as a strong promoter for epidermal growth factor receptor kinase and as a stimulator for cell growth.
Hanai N; Dohi T; Nores GA; Hakomori S
J Biol Chem; 1988 May; 263(13):6296-301. PubMed ID: 2834372
[TBL] [Abstract][Full Text] [Related]
19. Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.
Gabri MR; Otero LL; Gomez DE; Alonso DF
J Exp Clin Cancer Res; 2009 Dec; 28(1):146. PubMed ID: 19951433
[TBL] [Abstract][Full Text] [Related]
20. Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3.
Yamamoto S; Yamamoto T; Saxton RE; Hoon DS; Irie RF
J Natl Cancer Inst; 1990 Nov; 82(22):1757-60. PubMed ID: 1700134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
